Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia takes a shot at sepsis

Executive Summary

"You will be hearing more...in the fall" about the potential sepsis agent tifacogin, Pharmacia CFO Chris Coughlin tells the Goldman Sachs conference June 14. "It is a high risk area" and "we tend to be conservative and not try to tout these things too early," Coughlin says. The recombinant protein tissue factor pathway inhibitor, being developed in collaboration with Chiron, entered Phase III in mid-2000; interim data from the two-year, 1,500-patient trial will be analyzed around year-end (1"The Pink Sheet" Feb. 14, 2000, p. 33)

You may also be interested in...



Chiron/Searle Tifacogin Will Begin Two-Year, 1,500 Patient Trial In Sepsis

Chiron will initiate a pivotal, 1,500 patient trial of tifacogin in sepsis in the first half of the year, Chiron Chairman & CEO Sean Lance said during a Feb. 8 conference call announcing the company's sales and earnings for 1999.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
UsernamePublicRestriction

Register

PS038085

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel